Articles

Long considered a destination of choice for life science multinationals seeking to tap into the latent potential of Middle Eastern markets, the United Arab Emirates’ pharmaceuticals, medtech and healthcare sectors have all been exhibiting significant growth momentum in the post-pandemic period.   “Thanks to its comparatively attractive operating environment and strong business fundamentals, the UAE…

A charismatic force at the forefront of the country’s health transformation efforts, Dr Amin Al Amiri currently serves as assistant undersecretary at the UAE Ministry of Health as well as chairman of the UAE Supreme National Blood Transfusion Committee. In conversation earlier this year at BIO2023, Dr Al Amiri touched on five key ways in…

Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high salaries on offer were previously the main attractor to the country, with workers often staying for a couple of years before returning to their home…

With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and a high regional prevalence of genetic diseases, it seems that the stage is set for the UAE to assume a much more prominent role in…

While patient advocacy is still less prevalent in the United Arab Emirates (UAE) than in other parts of the world and there are no UAE patient organisations among the World Patients Alliance’s almost 400 members, the voice of patients in the UAE is becoming louder and beginning to get heard by both the pharma industry…

From humble origins, taiba can now count on a unique two decades of experience in bringing innovative rare disease products to patients across the MENA region. The Dubai headquartered company, now branding itself as the partner of choice for rare diseases across the region, has also moved to create a local manufacturing footprint to better…

As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover that the volatility of these geographies often meant that the expected returns did not materialise. However, especially post-COVID, emerging markets are once more being seen…